Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsDan Cravens - Vice President and Head of Investor RelationsDavid Endicott - CEOGraham Doyle - Executive Director and Head of European MedTechIssie Kirby - VP of Equity ResearchPatrick Wood - Managing Director and Head of the U.S. Medical Technology Equity Research TeamTim Stonesifer - CFOTom Stephan - VP of Healthcare Equity ResearchVeronika Dubajova - Managing DirectorConference Call ParticipantsAnthony Petrone - Manag ...

Core Viewpoint - The report from Citi indicates that JD Health is expected to maintain growth momentum in the second half of last year, driven by strong performance during the Double Eleven sales event and a surge in flu cases in December [1] Financial Performance - Revenue is projected to increase by 24.5% year-on-year to 37.1 billion yuan [1] - Adjusted EBIT is expected to double year-on-year to 2.1 billion yuan, supported by margin expansion and operational leverage [1] Profit Forecast - Citi has raised JD Health's adjusted net profit forecasts for the fiscal years 2026 and 2027 by 1% and 2% respectively, reflecting the recovery in drug sales and profit expansion prospects [1] - The firm maintains a "Outperform" rating and sets a target price of 71 HKD for JD Health [1]

Core Viewpoint - Morgan Stanley's report indicates that MicroPort Scientific Corporation (02252) has shown stronger-than-expected order trends in the first half of the year, reflecting a structural shift in growth and profitability drivers [1] Financial Performance - The company's revenue increased by 77% year-on-year, while net losses narrowed by 59% [1] - Overseas sales surged by 189%, accounting for 58% of total revenue, highlighting the significance of international business as a core growth engine [1] Future Guidance - Management has set a target for approximately 85% revenue growth for the year and aims to further reduce net losses [1] - The company plans to strictly control capital expenditures between 5 million to 10 million RMB, with a goal of keeping free cash outflow below 200 million RMB [1] Analyst Rating and Price Target - Morgan Stanley raised the target price from HKD 19.1 to HKD 30.9 and upgraded the rating from "Neutral" to "Overweight" based on the company's growth prospects [1]